Лекарственная терапия нейропатического болевого синдрома*

1. Алексеев В.В., Яхно Н.Н. Боль. Болезни нервной системы. Руководство для врачей. Под ред. Н.Н.Яхно, Д.Р.Штульмана. М.: Медицина, 2001; 1: 106–24.
2. Гусев Е.И., Камчатнов П.Р. Пластичность головного мозга в норме и патологии. Журн. невропатол. и психиатр. им. С.С.Корсакова. 2003; 11: 44–8.
3. Кукушкин М.Л., Хитров Н.К. Общая патология боли. М.: Медицина, 2004.
4. Attal N, Cruccu G, Haanpaa M et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13 (11): 1153–69.
5. Attal N, Cruccu G, Baron R et al. European Federation of Neurological Societies. Eur J Neurol 2010; 17 (9): 1113–88.
6. Cardenas D, Nieshoff E, Suda K. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology 2013; 80 (6): 533–9.
7. Devor M, Lomazov P, Matzner O. Sodium channel accumulation in injured axons as a substrate for neuropathic pain. Touch, temperature and pain in health and disease: mechanisms and assessments. Eds.: J.Boivie, P.Hansson, U.Lindblom. In: Progress in pain research and management series. Seattle: IASP Press 1994; 3: 207–30.
8. Dworkin R, Corbin A, Young J et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60 (8): 1274–83.
9. Freynhagen R, Strojek K, Griesing T. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115 (3): 254–63.
10. Freynhagen R, Rolke R, Baron R et al. Pseudoradicular and radicular low-back pain – a disease continuum rather than different entities? Answers from quantitative sensory testing. Pain 2008; 135 (1–2): 65–74.
11. Hansson P, Fields H, Hill R, Marchettini P. Neuropathic pain: pathophysiology and treatment, progress in pain research and management. Seattle, WA: IASP Press 2001; 21: 151–67.
12. Jacquy J, Lossignol D, Sternon J. Pregabalin (Lyrica) and neuropathic pain syndromes. Rev Med Brux 2006; 27 (5): 445–50.
13. Kim J, Bashford G, Murphy T. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain 2011; 152 (5): 1018–123.
14. Korff M, Saunders K. The course of back pain in primary care. Spine 1996; 21: 2833–7.
15. Kroenke K, Krebs E, Bair M. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiat 2009; 31 (3): 206–19.
16. Li C, Zhang X, Matthews E et al. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain 2006, 125: 20–34.
17. Lopez-Trigo J, Sancho Rieger J. Pregabalin. A new treatment for neuropathic pain. Neurologia 2006; 21 (2): 96–103.
18. Luo Z, Chaplan S, Higuera E et al. Upregulation of dorsal root ganglion alpha2delta calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001; 21: 1868–75.
19. LYRICA Study Group Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients. Int J Clin Pract 2006; 60 (9): 1060–7.
20. Maizels M, Mccarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. J Am Ac Fam Physicians 2005; 71 (3): 188–92.
21. Martinez J, Kasamatsu M, Rosales-Hernandez A et al. Comparison of central vs. peripheral delivery of pregabalin in neuropathic pain states. Molecular Pain 2012; 8 (1): 3. http://doi: 10.1186/ 1744-8069-8-3
22. Matthews E, Dickenson A. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 2001; 92: 235–46.
23. Moore R, Straube S, Wiffen P et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; 3: CD007076.
24. O’Connor A, Dworkin R. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122 (Suppl. 10): s22–32.
25. Richter R, Portenoy R, Sharma U. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6 (4): 253–60.
26. Romanò C, Romanò D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009; 10 (4): 185–91.
27. Rosenstock J, Tuchman M, La Moreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110 (3): 628–38.
28. Sabatowski R, Galvez R, Cherry DA. 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004; 109 (1–2): 26–35.
29. Siddall P, Cousins M, Otte A et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67 (10): 1792–800.
30. Tesfaye S, Boulton A, Dyck P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285–93.
31. Tesfaye S, Wilhelm S, Lledo A et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The COMBO-DN study – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013; 154 (12): 2616–25.
32. Tremont-Lukats I, Megeff C, Backonja M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000; 60 (5): 1029–52.
33. van Seventer R, Feister H, Young J et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006; 22 (2): 375–84.
34. Van Seventer R, Bach F, Toth C et al. Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol 2010; 17 (8): 1082–9.
35. Vinik A, Casellini C. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. J Diabetes Met Syndrome Obesity: Targets Ther 2013; 6: 57–78.
36. Waxman S, Cummins T, Dib-Hajj S et al. Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve 1999; 22: 1177–87.
37. White D, Zimmermann M. The bradykinin-induced release of substance P from nerve fibre endings in the rat saphenous nerve neuroma is not related to electrophysiological excitation. Neurosci Lett 1988; 92: 108–13.
38. Wiffen P, McQuay H, Edwards J, Moore R. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005; 3: CD005452.
39. Zhao Y, Sun P, Bernauer M. Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia. J Pain Research 2012; 5: 443–51.
40. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabet Met Res Rev 2008; 24 (Suppl. 1): s52–7.
41. Carey TS, Evans AT, Hadler NM et al. Acute severe low back pain. A population-based study of prevalence and care-seeking. Spine 1996; 21 (3): 339–44.
42. Loney PL, Stratford PW. The prevalence of low back pain in adults: a methodological review of the literature. Phys Ther 1999; 79 (4): 384–96.
43. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5 (3): 143–9.
44. Данилов А.Б. Управление болью. М.: АММ Пресс, 2012.

П.Р.Камчатнов1, М.А.Евзельман2

1. ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, Москва;
2. ФГБОУ ВПО Орловский государственный университет